目的:建立具有人免疫学特性的高转移肝癌SCID 鼠模型.方法:SCID小鼠腹腔注射人外周血淋巴细胞,皮下接种人高转移肝癌细胞MHCC97-H,免疫重建人高转移肝癌SCID小鼠模型,并鉴定建立的结果.结果:①免疫重建荷人高转移肝癌细胞小鼠的成瘤率为100% ,较荷瘤组成瘤潜伏期延长,体积缩小( P＜0.05);转移率为100%,其从皮下转移到肝脏所需时间较荷瘤组延长(P＜0.05).②第2、4、6周小鼠血中人IgG含量的测定:同期相比,人化荷瘤组小鼠血中人IgG含量高于人化组(P＜0.05). ③第6周SCID小鼠外周血中人CD3+T淋巴细胞和人CD20+ B淋巴细胞含量的测定:人化荷瘤组小鼠血中人CD3+T淋巴细胞和人CD20+ B淋巴细胞含量高于人化组(P＜0.05).④免疫组化检测人化荷瘤组小鼠脾脏中存在人CD3+ T 淋巴细胞和CD20+ B淋巴细胞.结论:成功建立免疫重建荷人高转移肝癌SCID 鼠模型,为肝癌转移的研究及治疗提供了理想的动物模型.%Objective:To explore the effective methods of establishing a human metastatic hepatocelluar carcinoma model in human peripheral blood lymphocyte (hu-PBL) engrafted to severe combined immunodeficient (SCID) mice.Methods:The immunological features of mice were evaluated after intra-peritoneal injection of hu-PBL and subcutaneous implantation of human high metastatic hepatocelluar carcinoma cells (MHCC97-Hs).Results:①Subcutaneous tumors developed in all the mice given hu-PBL and MHCC97-Hs.The latency period was significantly prolonged,and the tumor size was marked depressed,as compared with mice given human MHCC97-Hs alone.The tumor's metastatic time needed of the mice given hu-PBL and MHCC97-Hs was longer than the mice given human MHCC97-Hs alone.②In the 2nd,4th and 6th week,the amount of human IgG in the mice given hu-PBL and MHCC97-Hs was lager than the mice given MHCC97-Hs alone.③In the 6th week,the number of human CD3+ T lymphocytes and CD20+ B lymphocytes in the mice given hu-PBL and MHCC97-Hs was lager than the mice MHCC97-Hs alone.④Immunohistochemical staining revealed presence of remarkable human CD3+ T lymphocytes and CD20+ B lymphocytes in SCID mice spleen.Conclusion:A human high metastatic hepatocelluar carcinoma model has been established hu-PBL engrafted to SCID mice,which is an ideal animal model for preclinical research and treatment for metastatic of hepatocelluar carcinoma．
展开▼
